Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial Fibrillation: An Update

Journal of Cardiovascular Pharmacology

Volumn 66, Issue 6, 2015, Pages 523-529

  Gutierrez, Alejandra ^a   Van Wagoner, David R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

atrial ectopy; fibrosis; inflammation; myofibroblast; oxidant stress

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHEMOKINE; COLCHICINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FISH OIL; GLUCOCORTICOID; HISTONE DEACETYLASE INHIBITOR; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; METOPROLOL; MYELOPEROXIDASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AUTACOID; OXIDIZING AGENT;

ATRIAL FIBRILLATION; DIABETES MELLITUS; HEART ATRIUM REMODELING; HEART FAILURE; HEART SURGERY; HUMAN; HYPERTENSION; NONHUMAN; OBESITY; OXIDATIVE STRESS; POSTOPERATIVE ATRIAL FIBRILLATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SLEEP DISORDERED BREATHING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; TRENDS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ATRIAL FIBRILLATION; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION MEDIATORS; OXIDANTS; OXIDATIVE STRESS;

EID: 84950235697     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000313     Document Type: Review

References (67)

1. Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol. 2008;52:306-313.
2. Van Wagoner DR, Piccini JP, Albert CM, et al. Progress toward the prevention and treatment of atrial fibrillation: a summary of the heart rhythm society research forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. Heart Rhythm. 2015;12:e5-e29.
3. Oka S, Ago T, Kitazono T, et al. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. J Mol Med. 2009;87:785-791.
4. Liu F, Levin MD, Petrenko NB, et al. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol. 2008;45:715-723.
5. Artlett CM, Thacker JD. Molecular activation of the NLRP3 inflammasome in fibrosis: common Threads linking Divergent fibrogenic diseases. Antioxid Redox Signal. 2015;22:1162-1175.
6. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254-1268.
7. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39:44-84.
8. Jacob KA, Nathoe HM, Dieleman JM, et al. Inflammation in new-onset atrial fibrillation after cardiac surgery: a systematic review. Eur J Clin Invest. 2014;44:402-428.
9. Abdelhadi RH, Gurm HS, Van Wagoner DR, et al. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am J Cardiol. 2004;93:1176-1178.
10. Fontes ML, Amar D, Kulak A, et al. Increased preoperative white blood cell count predicts postoperative atrial fibrillation after coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2009;23:484-487.
11. Ishii Y, Schuessler RB, Gaynor SL, et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation. 2005;111:2881-2888.
12. Rudolph V, Andrie RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med. 2010;4:470-474.
13. Halonen J, Halonen P, Jarvinen O, et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA. 2007;297:1562-1567.
14. Liu C, Wang J, Yiu D, et al. The efficacy of glucocorticoids for the prevention of atrial fibrillation, or length of intensive care unite or hospital stay after cardiac surgery: a meta-analysis. Cardiovasc Ther. 2014; 32:89-96.
15. Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal antiinflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011;343:d3450.
16. Deftereos S, Giannopoulos G, Kossyvakis C, et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol. 2012;60: 1790-1796.
17. Imazio M, Brucato A, Ferrazzi P, et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011;124:2290-2295.
18. Imazio M, Brucato A, Ferrazzi P, et al; COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014; 312:1016-1023.
19. Zhang C, Chen B, Guo A, et al. Microtubule-mediated defects in junctophilin-2 trafficking contribute to myocyte transverse-tubule remodeling and Ca2+ handling dysfunction in heart failure. Circulation. 2014; 129:1742-1750.
20. Kim YM, Kattach H, Ratnatunga C, et al. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008; 51:68-74.
21. Ozaydin M, Dede O, Varol E, et al. Effect of renin-angiotensin aldosteron system blockers on postoperative atrial fibrillation. Int J Cardiol. 2008;127:362-367.
22. Rader F, Van Wagoner DR, Gillinov AM, et al. Preoperative angiotensin-blocking drug therapy is not associated with atrial fibrillation after cardiac surgery. Am Heart J. 2010;160:329-336.
23. Laufs U, Kilter H, Konkol C, et al. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res. 2002;53: 911-920.
24. Elgendy IY, Mahmoud A, Huo T, et al. Meta-analysis of 12 trials evaluating the effects of statins on decreasing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2015.
25. Antoniades C, Demosthenous M, Reilly S, et al. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll Cardiol. 2012; 59:60-70.
26. Dewland TA, Vittinghoff E, Mandyam MC, et al. Atrial ectopy as a predictor of incident atrial fibrillation: a cohort study. Ann Intern Med. 2013; 159:721-728.
27. Heijman J, Voigt N, Wehrens XH, et al. Calcium dysregulation in atrial fibrillation: the role of CaMKII. Front Pharmacol. 2014;5:30.
28. Thanassoulis G, Massaro JM, O'Donnell CJ, et al. Pericardial fat is associated with Prevalent atrial fibrillation: the Framingham heart study. Circ Arrhythm Electrophysiol. 2010;3:345-350.
29. Batal O, Schoenhagen P, Shao M, et al. Left atrial epicardial adiposity and atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3: 230-236.
30. Hatem SN, Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res. 2014;102:205-213.
31. Verheule S, Sato T, Everett T, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res. 2004;94:1458-1465.
32. Yeh YH, Kuo CT, Chan TH, et al. Transforming growth factor-{beta} and oxidative stress mediate tachycardia-induced cellular remodeling in cultured atrial-derived myocytes. Cardiovasc Res. 2011;91:62-70.
33. Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J. 2015;79: 495-502.
34. Abed HS, Samuel CS, Lau DH, et al. Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation. Heart Rhythm. 2013;10:90-100.
35. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of Ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64: 2222-2231.
36. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050-2060.
37. Matsui T, Oda E, Higashimoto Y, et al. Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE. Cardiovasc Diabetol. 2015;14:1.
38. Rude MK, Duhaney TA, Kuster GM, et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension. 2005;46:555-561.
39. Anne W, Willems R, Roskams T, et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. CardiovascRes. 2005;67:655-666.
40. Raposeiras-Roubin S, Rodino-Janeiro BK, Grigorian-Shamagian L, et al. Evidence for a role of advanced glycation end products in atrial fibrillation. Int J Cardiol. 2012;157:397-402.
41. Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114:1453-1468.
42. Linz D, Hohl M, Nickel A, et al. Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. Hypertension. 2013;62:767-74.
43. Lau DH, Shipp NJ, Kelly DJ, et al. Atrial arrhythmia in ageing spontaneously hypertensive rats: unraveling the substrate in hypertension and ageing. PLoS One. 2013;8:e72416.
44. Neilan TG, Farhad H, Dodson JA, et al. Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart Assoc. 2013;2:e000421.
45. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-1839.
46. Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, Alp NJ, Schotten U, Casadei B. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation. 2011; 124(10):1107-17.
47. Zhang J, Youn JY, Kim AY, et al. NOX4-Dependent hydrogen peroxide overproduction in human atrial fibrillation and HL-1 atrial cells: relationship to hypertension. Front Physiol. 2012;3:140.
48. Kuroda J, Ago T, Matsushima S, et al. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A. 2010;107:15565-15570.
49. Nishijima Y, Sridhar A, Bonilla I, et al. Tetrahydrobiopterin depletion and NOS2 uncoupling contribute to heart failure-induced alterations in atrial electrophysiology. Cardiovasc Res. 2011;91:71-79.
50. Altenhofer S, Radermacher KA, Kleikers PW, et al. Evolution of NADPH oxidase inhibitors: Selectivity and mechanisms for target engagement. Antioxid Redox Signal. 2014.
51. Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol. 2013;168: 5135-5142.
52. Dabrowski R, Borowiec A, Smolis-Bak E, et al. Effect of combined spironolactone-beta-blocker +/2 enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). American Journal of Cardiology. 2010; 106(11):1609-14.
53. Milliez P, Deangelis N, Rucker-Martin C, et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J. 2005;26:2193-2199.
54. Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE, et al. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc. 2014;3.
55. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012.
56. Ho JE, Yin X, Levy D, et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J. 2014;167:729-734.e1.
57. Yalcin MU, Gurses KM, Kocyigit D, et al. The association of serum Galectin-3 levels with atrial electrical and structural remodeling. J Cardiovasc Electrophysiol. 2015.
58. O'Shea KM, Chess DJ, Khairallah RJ, et al. omega-3 Polyunsaturated fatty acids prevent pressure overload-induced ventricular dilation and decrease in mitochondrial enzymes despite no change in adiponectin. Lipids Health Dis. 2010;9:95.
59. Sakabe M, Shiroshita-Takeshita A, Maguy A, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation. 2007;116:2101-2109.
60. Shah KB, Duda MK, O'Shea KM, et al. The cardioprotective effects of fish oil during pressure overload are blocked by high fat intake: role of cardiac phospholipid remodeling. Hypertension. 2009;54:605-611.
61. Cardinale JP, Sriramula S, Pariaut R, et al. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension. 2010;56:437-444.
62. Van Wagoner DR, Nattel S. Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy. J Mol Cell Cardiol. 2008;45:707-708.
63. Zhang D, Wu CT, Qi X, et al. Activation of histone deacetylase-6 induces contractile dysfunction through derailment of alpha-tubulin proteostasis in experimental and human atrial fibrillation. Circulation. 2014; 129:346-358.
64. Brundel BJ, Ke L, Dijkhuis AJ, et al. Heat shock proteins as molecular targets for intervention in atrial fibrillation. Cardiovasc Res. 2008;78: 422-428.
65. Deshmukh A, Barnard J, Sun H, et al. Left atrial transcriptional changes associated with atrial fibrillation susceptibility and persistence. Circ Arrhythm Electrophysiol. 2015;8:32-41.
66. Sidorova TN, Yermalitskaya LV, Mace LC, et al. Reactive gammaketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells. J Mol Cell Cardiol. 2014; 79:295-302.
67. Sidorova TN, Mace LC, Wells KS, et al. Hypertension is associated with preamyloid oligomers in human atrium: a missing link in atrial pathophysiology? J Am Heart Assoc. 2014;3:e001384.